Over the Forecast Year, Imatinib Drugs will register a CAGR of 4% in terms of revenue and the global market size will reach USD XX billion by 2029.
Imatinib Drugs Market Overview
Chronic eosinophilic leukaemia will continue to rise in the future, owing to the rising cancer prevalence. Chronic eosinophilic leukaemia (CEL) is a condition in which the eosinophil count in the peripheral blood is greater than 1500 l, also known as hyper-eosinophilia. Overproduction of eosinophils in the bone marrow is an uncommon myeloproliferative neoplasm. This imatinib medicine treats the condition by inhibiting the tyrosine kinase enzyme, which prevents aberrant eosinophils from forming. Imatinib is more effective in people with leukaemia caused by a genetic mutation. Furthermore, Imatinib medicine aids in the rapid improvement of blood counts and symptoms, which makes this drug popular among the targeted patient population and enhances the imatinib drug market's revenue growth.
Furthermore, the market is expected to develop as healthcare expenditures rise and government and private groups raise cancer awareness. Moreover, during the projection period, R&D activities linked to imatinib are expected to create additional prospects.
During the forecast period, the worldwide imatinib medication market is expected to develop significantly. The high prevalence of leukaemia around the world, as well as an increase in healthcare professionals' use of the imatinib medicine, are driving market expansion. Gastrointestinal Stromal Tumor (GIST) has seen a considerable increase in imatinib medicine demand, and the drug is expected to gain a significant market share. GIST is a form of tumour that develops in the gastrointestinal tract.
What is our Imatinib Drugs Market Scope?
|
Report Attributes
|
Report Details
|
|
Forecast Period 2022 to 2029 CAGR
|
CAGR of 4% during the review period (2022 to 2029).
|
|
By Drug Formulation
|
|
|
By Application
|
- Aggressive Systemic Mastocytosis (ASM)
- Chronic Eosinophilic Leukemia (CEL)
- Dermatofibrosarcoma Protuberans (DFSP)
- Gastrointestinal Stromal Tumors (GIST)
- Hyper-eosinophilic Syndrome (HES)
- Myelodysplastic Syndrome (MDS)
- Myeloproliferative Diseases (MPD)
- Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)
- Philadelphia Chromosome-positive Chronic Myeloid Leukemia (Ph+ CML)
|
|
By Companies
|
- Novartis
- Glenmark Pharmaceuticals Ltd.
- Sun Pharmaceuticals
- Actavis Generics
- Dr. Reddy's Laboratories
- Teva Pharmaceutical Industries Ltd.
- Sanofi S.A.
- Cipla Inc.
- Apotex Inc.
- Mylan Pharms Inc.
|
|
Regions Covered
|
- North America
- Europe
- Asia-Pacific
- Rest of the World
|
|
Countries Covered
|
- US
- Canada
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- Latin America
|
|
Base Year
|
2021
|
|
Historical Year
|
2016-2021
|
|
Forecast Year
|
2022-2029
|
|
Number of Pages
|
139
|
|
Customization Available
|
Yes, the report can be customized as per your needs
|
Who are the Major Players in Imatinib Drugs Market?
The Imatinib Drugs Market is growing at a very fast pace and has seen the focus of many local and regional vendors offering precise application products for multiple end users. The three dependencies for the status of major companies in the market are: company profile, profitable gross margin, the prices they charge. The main players in this market - Novartis, Glenmark Pharmaceuticals Ltd., Sun Pharmaceuticals, Actavis Generics, Dr. Reddy's Laboratories, Teva Pharmaceutical Industries Ltd., Sanofi S.A., Cipla Inc., Apotex Inc and Others
Industry News
Basel, October 29, 2021 — Novartis announced today that the US Food and Drug Administration (FDA) approved Scemblix® (asciminib) for the treatment of chronic myeloid leukemia (CML) in two distinct indications. The FDA granted Scemblix accelerated approval for adult patients with Philadelphia chromosome-positive CML in chronic phase (Ph+ CML-CP) previously treated with two or more tyrosine kinase inhibitors (TKIs), based on major molecular response (MMR) rate at 24 weeks; and full approval for adult patients with Ph+ CML-CP with the T315I mutation1. In accordance with the Accelerated Approval Program, continued approval for the first indication may be contingent upon verification and description of clinical benefit from confirmatory evidence1. Scemblix is the first FDA-approved CML treatment that works by binding to the ABL myristoyl pocket, and represents an important development for patients who experience resistance and/or intolerance to currently available TKI therapies1-3. Also known as a STAMP inhibitor in scientific literature, Scemblix is being studied across multiple treatment lines for CML-CP, including the ASC4FIRST Phase III study evaluating Scemblix as a first-line treatment2-18.
What are the major Applications, Drug Formulations for Imatinib Drugs?
By Drug Formulation, it is segmented into
By Applications it is segmented into
- Aggressive Systemic Mastocytosis (ASM)
- Chronic Eosinophilic Leukemia (CEL)
- Dermatofibrosarcoma Protuberans (DFSP)
- Gastrointestinal Stromal Tumors (GIST)
- Hyper-eosinophilic Syndrome (HES)
- Myelodysplastic Syndrome (MDS)
Imatinib Drugs Market Regional Analysis
The imatinib drug market is segmented on the basis of application, drug formulation, and geography. Based on application, it is divided into aggressive systemic mastocytosis (ASM), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST), hyper-eosinophilic syndrome (HES), myelodysplastic syndrome (MDS), myeloproliferative diseases (MPD), Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), and Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). Based on the drug formulation, the market is bifurcated into tablets and capsules. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Rest of the World
- Middle East & Africa
- Latin America
-
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Rest of the World
- Middle East & Africa
- Latin America
- INTRODUCTION
- MARKET DEFINITION
- MARKET DYNAMICS
- MARKET SEGMENTATION
- REPORT TIMELINES
- KEY STAKEHOLDERS
- RESEARCH METHODOLOGY
- DATA MINING
- SECONDARY RESEARCH
- PRIMARY RESEARCH
- SUBJECT MATTER EXPERT ADVICE
- QUALITY CHECK
- FINAL REVIEW
- DATA TRIANGULATION
- BOTTOM-UP APPROACH
- TOP-DOWN APPROACH
- RESEARCH FLOW
- EXECUTIVE SUMMARY
- INTRODUCTION
- GLOBAL IMATINIB DRUGS TREATMENT BY DRUG FORMULATION
- GLOBAL IMATINIB DRUGS BY APPLICATIONS
- MARKET DYNAMICS
- DRIVERS
- INCREASING DEMAND FOR IMATINIB DRUGS RESTRAINTS
- STRINGENT ENVIRONMENTAL REGULATIONS
- HIGH COST ON MATERIALS
- OPPORTUNITIES
- IMATINIB DRUGS GROWTH
- APPLICATION OF IMATINIB DRUGS
- IMPACT OF COVID 19
- GLOBAL IMATINIB DRUGS MARKET, BY DRUG FORMULATION INTRODUCTION
- CAPSULES
- TABLETS
- GLOBAL IMATINIB DRUGS MARKET, BY APPLICATION
- INTRODUCTION
- AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM)
- CHRONIC EOSINOPHILIC LEUKEMIA (CEL)
- DERMATOFIBROSARCOMA PROTUBERANS (DFSP)
- GASTROINTESTINAL STROMAL TUMORS (GIST)
- HYPER-EOSINOPHILIC SYNDROME (HES)
- MYELODYSPLASTIC SYNDROME (MDS)
- MYELOPROLIFERATIVE DISEASES (MPD)
- PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL)
- PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (PH+ CML)
- GLOBAL IMATINIB DRUGS MARKET, BY REGION
- NORTH AMERICA
- EUROPE
- GERMANY
- FRANCE
- UK
- ITALY
- RUSSIA
- REST OF EUROPE
- APAC
- CHINA
- SOUTH KOREA
- JAPAN
- INDIA
- AUSTRALIA
- ASEAN
- REST OF APAC
- MIDDLE EAST AND AFRICA
- SAUDI ARABIA
- UAE
- SOUTH AFRICA
- TURKEY
- REST OF MEA
- SOUTH AMERICA
- BRAZIL
- REST OF MEA
- ARGENTINA
- REST OF SOUTH AMERICA
- COMPETITIVE LANDSCAPE
- MERGERS, ACQUISITIONS, JOINT VENTURES, COLLABORATIONS,
- AND AGREEMENTS
- MARKET SHARE PERCENTAGE RANKING ANALYSIS
- STRATEGIES ADOPTED BY LEADING PLAYERS
- COMPANY PROFILES
- BUSINESS OVERVIEW
- COMPANY SNAPSHOT
- PRODUCT BENCHMARKING
- STRATEGIC INITIATIVES
- NOVARTIS
- GLENMARK PHARMACEUTICALS LTD.
- SUN PHARMACEUTICALS
- ACTAVIS GENERICS
- DR. REDDY'S LABORATORIES
- TEVA PHARMACEUTICAL INDUSTRIES LTD.
- SANOFI S.A.
- CIPLA INC.
- APOTEX INC.
- MYLAN PHARMS INC.
SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.
PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.
MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.
EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.
REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.
